Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hormone Care Clear all
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

NCT02675231
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions
Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
32
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional

Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer

NCT03949270
View directory record Official record
Conditions
Breast Cancer, Adherence, Medication, Side Effect
Interventions
BETA-Text text messaging intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 21, 2026, 11:46 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

NCT06151418
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 21, 2026, 11:46 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility and Acceptability of Peer Intervention for Improving Mental Health Among People Accessing Hormone Care

NCT07354113
View directory record Official record
Conditions
Hormone Care, Mild Depression, Anxiety
Interventions
Peer support group, Enhanced Usual Care (EUC)
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed No phase listed Observational

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

NCT02003417
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • High Point, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 21, 2026, 11:46 AM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Terminated Phase 2 Interventional Results available

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

NCT01439867
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions
Cinacalcet hydrochloride, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2189 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional

A Research Study for Latina Women With Breast Cancer

NCT04861896
View directory record Official record
Conditions
Cancer, Breast, Cancer-related Problem/Condition, Quality of Life, Hormone Dependent Neoplasms, Adherence, Medication
Interventions
"My Guide" (psychoeducation & self-management program)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional Results available

Culturally Aware AET Non-Initiation Intervention

NCT05465408
View directory record Official record
Conditions
Breast Cancer, Survivorship, Treatment Compliance, Treatment Adherence, Treatment Refusal
Interventions
Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Concord, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional Results available

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190
View directory record Official record
Conditions
Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
Interventions
Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Phase 2 Interventional

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

NCT02015559
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mucoadhesive oral wound rinse, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions
Tirzepatide
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Not applicable Interventional

Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing

NCT06629272
View directory record Official record
Conditions
Hypothyroidism
Interventions
D-THIO (Deprescribing Thyroid Hormone In Older Adults), Enhanced usual care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
View directory record Official record
Conditions
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions
AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional Results available

Four Way Crossover Closed Loop With Exercise Detection

NCT02862730
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 21, 2026, 11:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiologic Evaluation and Breast Density (READ)

NCT00117663
View directory record Official record
Conditions
Breast Cancer
Interventions
temporary discontinuation of hormone therapy for 1 month, temporary discontinuation of hormone therapy for 2 months
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
1,704 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 21, 2026, 11:46 AM EDT